|
Check Us Out Now!! We Are Hot!! AGRT,QLTI,SVVS,VTRO,VICL,CBAK:: Sign Up Now!!
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: AGRT) AGR Tools, Inc., (NASDAQ: QLTI) QLT, Inc., (NASDAQ: SVVS) SAVVIS, Inc., (NASDAQ: VTRO) Vertro, Inc., (NASDAQ: VICL) Vical Inc., (NASDAQ: CBAK) China BAK Battery, Inc.
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
---------------------------
(OTCBB: AGRT - AGR Tools, Inc.)
LATEST NEWS!!
AGR Experiences Recent Surge in Dealer Interest
CONROE, TX, Dec 21, 2009 -- AGR Tools, Inc. is pleased to announce that AGR Stone & Tools USA, Inc., with which AGR Tools, Inc. has entered into a binding share exchange agreement, has experienced a recent surge in dealer interest due to its recent appearance in a feature on Business Television, or BTV. Since the company was profiled on BTV, AGR Stone & Tools USA, Inc. has fielded inquiries from 22 potential distributors and retailers, each of which represents an estimated minimum of $250,000 in annual sales. The company is currently in negotiations with five of these potential dealers but has not yet reached any definitive agreements.
The possible expansion of AGR Stone & Tools USA, Inc.'s dealership network represented by this interest will be instrumental in achieving the objectives the company has outlined for 2010. The Company plans to add to its growing list of distribution centers throughout North America, with Northern Illinois as the most recent addition to its network of 21 distributors in 15 states and provinces in the United States and Canada.
As the only major manufacturer of diamond tools that markets and distributes its products directly to their customers, AGR Stone & Tools USA, Inc. has a major advantage over its competition. By selling directly, it plans to control a quarter of the approximately $8 billion North American diamond tool market. "The recent influx of requests from distributors and retailers illustrates that our expansion strategy is progressing as planned," stated Rock Rutherford, the CEO of AGR Stone & Tools USA, Inc. "We are pleased with the level of interest in our products and the steps we are taking towards realizing our goal of capturing 25% of the diamond tool market." About AGR Stone & Tools USA, Inc.
---------------------------------
AGR Stone & Tools USA, Inc. is a major supplier of diamond tools and adhesives. It specializes in producing consumable tools for the natural stone, engineered stone, concrete and masonry industries. Its goal is to provide its clients with superior quality products, excellent customer service and the most competitive prices in the diamond tool industry. The company has completed extensive research and testing, and uses the latest technologies to assure AGR Tools is at the forefront of the diamond tool industry. The company employs some of the world's top scientists, engineers and metallurgists to produce the highest quality diamond tools for the construction industry.
On October 29, 2009, AGR Tools, Inc. and AGR Stone & Tools USA, Inc. entered into a binding share exchange agreement. See AGR Tools, Inc.'s Current Report on Form 8-K filed on November 2, 2009 regarding the new share exchange agreement with AGR Stone & Tools USA, Inc. for details on various conditions which must be met before the share exchange between the two companies closes. There can be no assurance that the share exchange will close. AGR Tools, Inc must issue 46,186,516 shares of its common stock to the current shareholders of AGR Stone & Tools USA, Inc. in order to complete the share exchange. Accounting for the anticipated cancellation of 25,000,000 shares of its common stock, upon the closing of the share exchange AGR Tools, Inc. will have 81,186,516 shares of common stock issued and outstanding.
More information on AGR Stone & Tools USA, Inc. can be found at: www.agrtools.com
---------------------------
(NASDAQ: QLTI - QLT, Inc.)
LATEST NEWS!!
QLT Inc. establishes sales force in the United States
VANCOUVER, Dec. 22, 2009 -- QLT Ophthalmics, Inc. will market Visudyne(R) to retinal specialists across the U.S.- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S. from Novartis Pharma AG ("Novartis") effective January 1, 2010 as a result of the Amended and Restated PDT Product Development, Manufacturing and Distribution Agreement with Novartis, previously announced on October 19, 2009, under which QLT will receive exclusive U.S. rights to the Visudyne patents to sell and market Visudyne in the U.S. Novartis will remain responsible for the distribution, sale and marketing of Visudyne in all other countries where the product is sold.
Scott Jones has joined QOI as Director, Commercial Operations, to manage the operations of the business unit, including those of the Visudyne sales force. Prior to joining QOI, Mr. Jones served in multiple positions within Novartis AG, most recently serving as Executive Director, Health Policy. Previously, Mr. Jones also held positions in Novartis Ophthalmics Inc., Novartis Tissue Engineering, and Novartis Transplant/Immunology and began his career in sales at Ciba/Geigy Pharmaceuticals.
"We are excited to announce the formation of a direct sales force that will focus on U.S. Visudyne sales. This is an important milestone in the history of the Company, and could pave the way for expansion of commercial operations with other ocular products," said Bob Butchofsky, President and Chief Executive Officer of QLT. "QOI is committed to ensure Visudyne remains a valuable treatment option for the millions of patients that have been or will be treated for wet age-related macular degeneration." About QLT Ophthalmics, Inc. (QOI) QOI is a wholly-owned U.S. subsidiary of QLT Inc. QOI was formed to commercialize QLT pharmaceutical and device products for the ophthalmic community. QOI's current mission is to support and market Visudyne across the U.S. territories including the Mid-Atlantic, Southeast, Northeast, Mid-West, and West regions by focusing directly on retinal specialists in the ophthalmic community.
About Visudyne Visudyne therapy is a two-step procedure involving the intravenous administration of the drug into the patient's arm. A non-thermal laser light is then shone into the patient's eye to activate the drug. This produces a reaction that closes the abnormal leaky vessels, resulting in a stabilization of the corresponding vision loss.
Visudyne is approved worldwide for the treatment of a form of wet AMD, the leading cause of legal blindness in people over the age of 55, and has been used in more than two million treatments worldwide. Visudyne is commercially available in more than 80 countries for the treatment of predominantly classic subfoveal CNV. In addition, over 60 countries have approved Visudyne to treat other macular neovascular conditions such as minimally classic and occult with no classic AMD lesions, pathological myopia and presumed ocular histoplasmosis.
About QLT QLT Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative therapies for the eye. We are focused on our commercial product Visudyne(R) for the treatment of wet-AMD, and the development of drugs to be delivered in our proprietary punctal plug devices. For more information, visit our website at www.qltinc.com.
---------------------------
(NASDAQ: SVVS - SAVVIS, Inc.)
LATEST NEWS!!
Peopleclick Deploys Savvis Global IT Infrastructure Solution
--Leading Talent Acquisition Solutions Provider Deploys Software-as-a-Service Model to Drive Global Expansion
ST. LOUIS, Dec 22, 2009 -- Savvis, Inc. (Nasdaq: SVVS), a global leader in outsourced internet infrastructure services for the enterprise, today announced completion of its software-as-a-service (SaaS) solution powering Peopleclick, the leading provider of global talent acquisition and workforce compliance and diversity solutions.
Peopleclick is an industry leader in providing web-based software and services that help global companies find, attract and hire quality people--in less time, with less risk. The Savvis IT infrastructure solution underpins a database of more than 90 million resumes in Peopleclick's unique talent acquisition system that provides transparency across organizations and supplies clients with the advanced technology to recruit top talent worldwide.
As part of the three year, IT infrastructure services agreement, Peopleclick is deploying Savvis' SaaS IT infrastructure solution to complement Peopleclick's global expansion strategy and expectations for growth. The solution is hosted from multiple Savvis data centers in the US and UK, including its facility on the outskirts of London in Slough, and will provide Peopleclick customers with high levels of security, reliability and performance.
"Due to the extensive growth and expansion around the globe, Peopleclick has invested in a new data centre to support our expanding international client base," said Thomas Bright, Sr. Chief Operating Officer at Peopleclick. "Savvis has been an outstanding provider in hosting our US-based data centre, and we are looking forward to extending this relationship in the United Kingdom as well." "We are pleased to provide Peopleclick with an IT infrastructure platform that forms the foundation for their SaaS service delivery model," said Bryan Doerr, CTO of Savvis. "As Peopleclick continues to lead the way in talent acquisition, we look forward to building a long term relationship as a trusted IT infrastructure services provider." Savvis currently operates 28 data centers globally, with more than 1.4 million square feet of high-quality raised floor space designed to support enterprise IT operations. In addition, Savvis was recently positioned as a leader in the Gartner Magic Quadrant for Web Hosting and Cloud Infrastructure (on Demand), 2009 www.savvis.net/magicquadrantleader About Peopleclick Peopleclick provides software and services that empower companies around the world to find, attract and hire quality people-in less time, with less risk. Peopleclick's technology, consulting expertise and support give companies the vision and flexibility to strategically manage all of their talent resources-whether they are salaried, hourly or contingent. Founded in 1997, the privately-held company currently serves over 2,000 clients in 214 countries and territories, including 54 of the Fortune 100. Peopleclick products support users in organizations ranging in size from large, multi-national corporations to small and medium-sized businesses. For more information about Peopleclick, visit www.peopleclick.com.
About Savvis Savvis, Inc. (Nasdaq: SVVS) is a global leader in outsourced internet infrastructure services for the enterprise. More than 4,000 customers, including 40% of the top 100 companies in the Fortune 500, use Savvis to reduce capital expense, improve service levels and harness the latest advances in cloud computing. For more information about Savvis, visit www.savvis.net
---------------------------
(NASDAQ: VTRO - Vertro, Inc.)
LATEST NEWS!!
Vertro, Inc. Announces Dismissal of Securities Class Action Lawsuit
NEW YORK, NY, Dec 22, 2009 -- Vertro, Inc. (NASDAQ: VTRO) today announced that the United States District Court for the Middle District of Florida granted Vertro's motion for summary judgment and entered judgment in favor of the defendants in the consolidated shareholder securities class action, titled In Re MIVA, Inc. Securities Litigation, which had been filed against Vertro and certain of Vertro's former officers and directors.
The Court ruled that plaintiffs could not prevail on their claims of alleged violations of Section 10(b) of the Securities Exchange Act of 1934 (the "Act") against Vertro and the individual defendants and on their claims that the individual defendants also violated Section 20(a) of the Act as "control persons" of Vertro. Vertro had previously disclosed in its Form 10-Q for the quarter ended September 30, 2009, that the Magistrate Judge issued a report recommending Vertro's motion for summary judgment be granted. Plaintiffs have filed a notice of their intention to appeal this decision to the Eleventh Circuit Court of Appeals.
About Vertro, Inc.
Vertro, Inc. (NASDAQ: VTRO) is a software and technology company that owns and operates the ALOT product portfolio. ALOT's products are designed to 'Make the Internet Easy' by enhancing the way consumers engage with content online. Through ALOT, Internet users can discover best-of-the-web third party content and display that content through customizable toolbar, homepage and desktop products. ALOT has millions of live users across its product portfolio. Together these users conduct high-volumes of type-in search queries, which are monetized through third-party search and content agreements.
---------------------------
(NASDAQ: VICL - Vical Inc.)
LATEST NEWS!!
Vical and the University of Washington Receive U.S. Patent for Herpes Simplex DNA Vaccine
SAN DIEGO, Dec 22, 2009 -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type 2 (HSV-2). HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Vical is collaborating under a previously disclosed grant(1) on the preclinical development of an HSV-2 vaccine which will be designed for use in people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral shedding and transmission. The vaccine will be evaluated with Vical's Vaxfectin(R) adjuvant. The new '993 patent covers DNA vaccines targeting a specific HSV-2 protein, formulated with or without Vical's Vaxfectin(R) adjuvant. It adds to Vical's family of patents in the United States and other key regions based on the company's discovery that administering genetic sequences such as DNA or RNA into the body, without the use of viral delivery vehicles, may cause expression of the proteins encoded by the genetic sequences. Vical has additional issued patents covering the composition and use of the Vaxfectin(R) adjuvant.
DNA vaccines encode certain proteins associated with a target pathogen, rather than using any part of the pathogen itself, and can prime the immune system as well as induce potent antibody and T-cell immune responses. DNA vaccines contain no viral particles, are non-infectious, and can be administered on a repeat basis without unwanted immune responses. Additionally, DNA vaccines have the potential to achieve proof of concept more quickly and cost-effectively than conventional vaccines, and can be manufactured using uniform methods of fermentation and purification, allowing significantly faster development and production.
HSV-2 Disease Burden HSV-2 infections are persistent and result in periodic virus shedding. In the United States, at least 40 million people are infected with HSV-2, and approximately 1.6 million people are newly infected each year, with approximately 500,000 of those suffering from disease symptoms. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV. There is currently no approved vaccine for HSV-2. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost over the years and potential for drug resistance highlight the need for safe, new approaches to reducing HSV-2 lesions, shedding, and transmission. Estimated direct costs of treating HSV-2 in the United States alone are close to $1 billion annually, primarily for drugs and outpatient medical care, plus additional indirect costs of more than $200 million.
About Vical Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
---------------------------
(NASDAQ: CBAK - China BAK Battery, Inc.)
LATEST NEWS!!
China BAK Announces Executing of High Power Battery Supply Contract
SHENZHEN, China, Dec 22, 2009 -- China BAK Battery, Inc. ("China BAK", the "Company" or "we") (Nasdaq: CBAK), one of the largest lithium-ion battery cell manufacturers in the world, as measured by production output, today announced its Tianjin Facility has begun to execute a contract with Jilin Hi-tech Electric Vehicle Co., Ltd, an affiliated company of First Automobile Group Co., Ltd, one of the largest automobile manufacturers in China, for providing high-power batteries used in its Electric Bus Project. The contract, amounting to approximately one million dollars, aims to provide battery packs and battery management systems for 20 electric buses.
"We are glad to see our Tianjin facility begin to execute its contract with Jilin Hi-tech Electric Vehicle Co., Ltd. This is our first order for batteries for electric buses. It represents customers' confidence in our products, and is a new and significant stage in China BAK's product development," commented Mr. Xiangqian Li, CEO of China BAK, "With significant government subsidies, we believe electric buses have the biggest potential in the foreseeable electric vehicle industry in China, and we are well prepared to grasp that opportunity." About China BAK Battery Inc.
China BAK Battery, Inc. is one of the largest manufacturers of lithium-based battery cells in the world, as measured by production output. It produces battery cells that are the principal component of rechargeable batteries commonly used in cellular phones, notebook computers and portable consumer electronics, such as digital media devices, portable media players, portable audio players, portable gaming devices, and PDAs. China BAK Battery, Inc.'s 3.0-million-square-foot facilities are located in Shenzhen and Tianjin, PRC, and have been recently expanded to produce new products.
---------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]
|
